MLTX · MoonLake Immunotherapeutics
$16.74
+0.40 (+2.45%)
At close · Aug 19
Market Cap
$1.39B
Shares
85.11M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-10 | 2026-06-30 | |
| 8-K | 2026-08-10 | — | |
| 8-K | 2026-07-15 | 2026-07-14 | |
| 8-K | 2026-06-25 | 2026-06-23 | |
| 8-K | 2026-06-22 | 2026-06-21 | |
| 8-K | 2026-06-09 | 2026-06-04 | |
| 8-K | 2026-06-01 | 2026-05-22 | |
| 8-K | 2026-05-11 | 2026-05-10 | |
| 10-Q | 2026-05-11 | 2026-03-31 | |
| DEF 14A | 2026-04-21 | 2026-06-04 | |
| 10-K | 2026-02-25 | 2025-12-31 | |
| 8-K | 2026-02-23 | 2026-02-18 | |
| 8-K | 2026-01-08 | — | |
| 8-K | 2025-11-05 | — | |
| 10-Q | 2025-11-05 | 2025-09-30 | |
| 8-K | 2025-11-05 | — | |
| 8-K | 2025-09-29 | — | |
| 8-K | 2025-08-05 | — | |
| 10-Q | 2025-08-05 | 2025-06-30 | |
| 8-K | 2025-06-06 | 2025-06-05 | |
| 10-Q | 2025-05-12 | 2025-03-31 | |
| 8-K | 2025-05-12 | — | |
| 8-K | 2025-04-29 | — | |
| DEF 14A | 2025-04-22 | 2025-06-05 | |
| 8-K | 2025-04-03 | 2025-03-31 | |
| 8-K | 2025-02-26 | — | |
| 10-K | 2025-02-26 | 2024-12-31 | |
| 8-K | 2024-12-18 | 2024-12-12 | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-11-07 | — | |
| 8-K | 2024-09-11 | — | |
| 8-K | 2024-08-07 | — | |
| 10-Q | 2024-08-07 | 2024-06-30 | |
| 8-K | 2024-06-10 | — | |
| 8-K | 2024-06-06 | 2024-06-05 | |
| 10-Q | 2024-05-07 | 2024-03-31 | |
| 10-K/A | 2024-05-07 | 2023-12-31 | |
| 8-K | 2024-05-07 | — | |
| DEF 14A | 2024-04-24 | 2024-06-05 | |
| 8-K | 2024-03-11 | 2024-03-10 | |
| 10-K | 2024-02-29 | 2023-12-31 | |
| 8-K | 2024-02-29 | — | |
| 8-K | 2024-02-26 | — | |
| 10-Q | 2023-11-14 | 2023-09-30 | |
| 8-K | 2023-11-14 | — | |
| 8-K | 2023-11-06 | 2023-11-05 | |
| 8-K | 2023-10-16 | 2023-10-15 | |
| 8-K | 2023-09-11 | — | |
| 8-K | 2023-09-01 | 2023-08-30 | |
| 10-Q | 2023-08-10 | 2023-06-30 |
Showing 1–50 of 84 filings
Key facts
CIK
1821586
CUSIP
61559X104
13F (30d)
173 filings
167 filers
Visit website
Investor relations